Voronoi Inc
KOSDAQ:310210
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Voronoi Inc
Cash & Cash Equivalents
Voronoi Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash & Cash Equivalents
₩10.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash & Cash Equivalents
₩1.1T
|
CAGR 3-Years
27%
|
CAGR 5-Years
10%
|
CAGR 10-Years
22%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cash & Cash Equivalents
₩105.6B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash & Cash Equivalents
₩6.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash & Cash Equivalents
₩66.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash & Cash Equivalents
₩112B
|
CAGR 3-Years
65%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Voronoi Inc
Glance View
Voronoi, Inc. engages in the manufacture of novel kinase inhibitors and target protein degrader drugs. The company is headquartered in Incheon, Incheon. The company went IPO on 2022-06-24. The firm is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The firm is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results.
See Also
What is Voronoi Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
10.2B
KRW
Based on the financial report for Dec 31, 2024, Voronoi Inc's Cash & Cash Equivalents amounts to 10.2B KRW.
What is Voronoi Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
57%
Over the last year, the Cash & Cash Equivalents growth was -21%. The average annual Cash & Cash Equivalents growth rates for Voronoi Inc have been -18% over the past three years , 57% over the past five years .
